Preview

Онкоурология

Расширенный поиск

Современные возможности лечения несветлоклеточного почечно-клеточного рака

https://doi.org/10.17650/1726-9776-2015-11-4-24-33

Полный текст:

Аннотация

Несветлоклеточный почечно-клеточный рак представлен несколькими гистологическими вариантами. Биология опухоли существенно влияет на течение заболевания. Несмотря на единство хирургического лечения светлоклеточного и несветлоклеточного рака почки, прогноз пациентов с формально одинаковыми стадиями может отличаться. Чувствительность опухоли к лекарственной терапии также зависит от гистологического подтипа. В статье подробно рассматриваются современные возможности лечения папиллярного, хромофобного и других видов почечно-клеточного рака.

Об авторе

И. В. Тимофеев
Российское общество клинической онкологии
Россия

Бюро по изучению рака почки, 

109147, Москва, пер. Маяковского, 2



Список литературы

1. Алексеев Б.Я., Анжиганова Ю.В., Лыков А.В. и др. Особенности диагностики и лечения рака почки в России: предварительные результаты многоцентрового кооперированного исследования. Онкоурология 2012;(3):24–30. [Alekseyev B.Ya., Anzhiganova Yu.V., Lykov A.V. et al. Some specific features of the diagnosis and treatment of kidney cancer in Russia: preliminary results of a multicenter cooperative study. Onkourologiya = Oncourology 2012;(3):24–30. (In Russ.)].

2. Tsimafeyeu I., Aksel E. Renal cell carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1–4.

3. Srigley J.R., Delahunt B., Eble J.N., Egevad L. et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 2013;37(10):1469–89.

4. Moch H., Artibani W., Delahunt B. et al. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 2009;56(4):636–43.

5. Yamashita S., Ioritani N., Oikawa K. et al. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis. Int J Urol 2007;14(8):679–83.

6. Winters B.R., Gore J.L., Holt S.K. et al. Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol 2015 Aug 26. pii: S1078-1439(15)00360-9.

7. Lughezzani G., Jeldres C., Isbarn H. et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol 2009;182(4):1287–93.

8. Iacovelli R., Modica D., Palazzo A. et al. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J 2015;9(3–4):172–7.

9. Steffens S., Janssen M., Roos F.C. et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer 2012;48(15):2347–52.

10. Bratslavsky G., Boris R.S. Emerging strategies of nephron sparing surgery in patients with localized and recurrent renal cell carcinoma. Malign Tumours 2010;1:5–14.

11. van Poppel H., Da Pozzo L., Albrecht W. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephronsparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59(4):543–52.

12. Roos F.C., Steffens S., Junker K. et al. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014;14:372.

13. Zargar-Shoshtari K., Sharma P., Espiritu P. et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol 2015;33(3):112.e23–9.

14. Abel E.J., Margulis V., Bauman T.M. et al. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus; a contemporary multicenter analysis. BJU Int 2015. doi: 10.1111/bju.13268.

15. Tilki D., Nguyen H.G., Dall'Era M.A. et al. Impact of histologic subtype on cancerspecific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 2014;66(3):577–83.

16. Padrik P. Treatment of non-clear cell renal carcinoma. Malign Tumours 2010;1:35–8. doi: 10.18027/2224-5057-2011-1-40-44.

17. Motzer R.J., Bacik J., Schwarz L. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–63.

18. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81.

19. Kroeger N., Xie W., Lee J.L., Bjarnason G.A. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119(16):2999–3006.

20. Волкова М.И., Климов А.В. Роль паллиативной нефрэктомии в лечении диссеминированного рака почки в эру таргетной терапии. Злокачественные опухоли 2012;2(2):58–60. [Volkova M.I., Klimov A.V. The role of palliative nephrectomy for metastatic renal cell carcinoma in the era of targeted agents. Malignant tumours 2012;2(2):58–60. (In Russ.)].

21. Tsimafeyeu I., Zart J.S., Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. BJU International 2013;112 (1):32–8.

22. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65.

23. Tsimafeyeu I., Snegovoy A., Varlamov S. et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol 2015;10(3):423–7.

24. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 1.2016.

25. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014;25 Suppl 3:iii49–56.

26. Dutcher J.P., de Souza P., McDermott D. et al. Effect of temsirolimus versus interferonalpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202–9.

27. Tannir N.M., Jonasch E., Altinmakas E. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 2014;32:5 (suppl; abstr 4505).

28. Armstrong A.J., Broderick S., Eisen T. et al. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 2015;33 (suppl; abstr 4507).

29. Escudier B.J., Bracarda S., Rey J.P. et al. Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology. J Clin Oncol 2014;32 (suppl 4; abstr 410).

30. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients. J Clin Oncol 2009;7(22):3584–90.

31. Иванов С.А., Клименко А.А., Добровольская Н.Ю. Длительное применение бевацизумаба с интерфероном альфа в качестве первой линии таргетной терапии распространенного рака почки. Злокачественные опухоли 2014;2(9):37–42. [Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Long-term treatment of bevacizumab combined with interpheron alpfa in the first-line targeted therapy for metastatic renal cell carcinoma. Malignant tumours 2014;2(9):37–42. (In Russ.)].

32. Koh Y., Lim H.Y., Ahn J.H. et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013;24(4):1026–31.

33. Hutson T.E., Escudier B., Esteban E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(8):760–7.

34. Schrader A.J., Seseke S., Keil C. et al. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer. Eur Urol 2014;66(2):275–81.

35. Каприн А.Д., Иванов С.А., Клименко А.А., Добровольская Н.Ю. Пример применения ингибитора тирозинкиназ в качестве таргетной терапии при светлоклеточном варианте рака почки. Злокачественные опухоли 2015;1(12):49–52. [Kaprin A.D., Ivanov S.A., Klimenko A.A., Dobrovolskaya N.U. Example of the first-line targeted therapy with tyrosine kinase inhibitor in the treatment of clear cell renal cell carcinoma. Malignant tumours 2015;1(12):49–52. (In Russ.)].

36. Tsimafeyeu I., Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res Ther 2010;6(4):575–7.

37. Česas A., Mikutaitė V. Successful Treatment of metastatic renal cell carcinoma with sunitinib. Malign Tumours 2010;1:39–40.

38. Gore M.E., Szczylik C., Porta C. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113(1):12–9.

39. Ravaud A., Oudard S., De Fromont M. et al. First line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP - a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). Ann Oncol 2012;23(suppl 9):ix258–ix293.

40. Lee J.L., Ahn J.H., Lim H.Y. et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23(8):2108–14.

41. Bilen M.A., Zurita A.J., Ilias-Khan N.A. et al. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: results from a phase II trial. Oncologist 2015;20(10):1140–8.

42. Tannir N.M., Plimack E., Ng C. et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62(6):1013–9.

43. Stadler W.M., Figlin R., McDermott D. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272–80.

44. Stadler W.M., Figlin R.A., Ernstoff M.S. et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with nonclear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2007;25(18): suppl 5036.

45. Beck J., Procopio G., Bajetta E. et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011;22(8):1812–23.

46. Jäger D., Ma J.H., Mardiak J. et al. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study. Clin Genitourin Cancer 2015;13(2): 156–64.

47. Gordon M.S., Hussey M., Nagle R.B. et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27(34):5788–93.

48. Iyevleva A.G., Novik A.V., Moiseyenko V.M., Imyanitov E.N. EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol 2009;27(5):548–50.

49. Владимирова Л.Ю., Абрамова Н.А., Шихлярова А.И. Метаболическая модуляция противоопухолевого эффекта цитостатиков в эксперименте и клинике. Злокачественные опухоли 2014;3(10):42–7. [Vladimirova L.U., Abramova N.A., Shihlyarova A.I. Metabolic modulation of the antitumor cytostatic activity in vitro and in vivo. Malignant tumours 2014;3(10):42–7. (In Russ.)].

50. Насхлеташвили Д.Р. Cовременные возможности лекарственной терапии больных раком почки с метастатическим поражением головного мозга. Злокачественные опухоли 2012;2(2):61–7. [Naskhletashvili D.R. Current therapeutic approaches in renal cell cancer patients with brain metastases. Malignant tumours 2012;2(2):61–7.(In Russ.)].

51. Tsimafeyeu I., Demidov L., Kharkevich G. et al. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. Am J Clin Oncol 2012;35:251–4.

52. Oudard S., Banu E., Vieillefond A. et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007;177:1698–702.

53. Bylow K., Atkins M., Posadas E. et al. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009;7:39–42.

54. Richey S.L., Tamboli P., Ng C.S. et al. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2013;36(5):450–4.

55. Федянин М.Ю. Персонализированная терапия в онкологии: настоящее и будущее. Злокачественные опухоли 2012;8(3):24–30. [Fedyanin M.U. Personalized medicine in oncology: current and future. Malignant tumours 2012;8(3):24–30. (In Russ.)].

56. Golovine K., Makhov P., Naito S. et al. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 2015;16(5):743–9.

57. Tsimafeyeu I., Wynn N., Gordiyev M., Khasanova A. FGFR2 expression and mutation are rare in papillary renal cell carcinoma [abstr]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl): abstr 4069. doi:10.1158/1538-7445.AM2013-4069.

58. Atkins M.B., Gravis G., Drosik K. et al. Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-label, multicenter, phase II study. J Clin Oncol 2015 [epub ahead of print]. doi: 10.1200/JCO.2014.60.6012.


Для цитирования:


Тимофеев И.В. Современные возможности лечения несветлоклеточного почечно-клеточного рака. Онкоурология. 2015;11(4):24-33. https://doi.org/10.17650/1726-9776-2015-11-4-24-33

For citation:


Tsimafeyeu I.V. Current treatment approach to non-clear cell renal carcinoma. Cancer Urology. 2015;11(4):24-33. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-4-24-33

Просмотров: 635


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)